Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lindsay Chalmers

Nurse Practitioner, Acute Care Little Rock, AR Nurse Practitioner

NPI 1285873984 CMS profile 10758352

7 Shackleford West Blvd, Little Rock, AR 72211

Open in the dashboard

General payments

$4,449

69 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsay Chalmers of Little Rock, AR is reported in the CMS Open Payments database as having received $4,449 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $71 3
2024 General $267 7
2023 General $2,085 29
2022 General $1,818 22
2021 General $208 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsay Chalmers
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Lindsay Chalmers were reported at $71. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Lindsay Chalmers Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $208 $123 $38–$327 $132
2022 $1,818 $130 $44–$369 $149
2023 $2,085 $144 $49–$410 $160
2024 $267 $146 $48–$433 $164
2025 $71 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Silk Road Medical, Inc. $1,902 19 payments
  2. Medtronic, Inc. $1,604 11 payments
  3. Atricure, Inc. $270 20 payments
  4. Stryker Corporation $124 4 payments
  5. Abiomed $122 1 payment
  6. Boston Scientific Corporation $118 3 payments
  7. Terumo Cardiovascular Systems Corporation $81 1 payment
  8. Abbott Laboratories $58 2 payments
  9. Pfizer Inc. $35 2 payments
  10. LeMaitre Vascular, Inc. $32 1 payment
  11. Other $104 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $2,386 9 payments
  2. Food and Beverage $2,050 59 payments
  3. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,902 19 payments
  2. ENROUTE Transcarotid Stent $1,902 19 payments
  3. Octopus $1,340 9 payments
  4. SYNERGY ABLATION SYSTEM $157 12 payments
  5. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $142 1 payment
  6. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $142 1 payment
  7. NA $124 4 payments
  8. Impella $122 1 payment
  9. WATCHMAN $118 3 payments
  10. ATRICLIP LAA EXCLUSION SYSTEM $109 7 payments
  11. Other $499 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

275

Median for Nurse Practitioner: 389

Drug cost

$11,940

Median for Nurse Practitioner: $21,885

Branded share of claims

20.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 18 $10,543
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $323
Metoprolol Tartrate Generic 84 $317
Potassium Chloride Generic 29 $256
Amiodarone Hcl Generic 17 $189
Atorvastatin Calcium Generic 26 $177
Furosemide Generic 36 $91
Tramadol Hcl Generic 14 $29
Amlodipine Besylate Generic 13 $16

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$11,048

Medicare's payments for the services billed

Medicare patients

54

Average age 73

Services billed

153

19 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Atrial fibrillation 67%
Diabetes 50%
Arthritis 43%
COPD 41%
Heart failure 39%
Chronic kidney disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record